PCI Pharma Services ("PCI" or the "Company"), a world-leading global contract development and manufacturing organization ...

PCI Pharma Services has received a strategic investment co-led by Bain Capital and existing lead investor Kohlberg, and ...

The new investment will support both organic and inorganic expansion, including growth in sterile fill-finish injectables, ...

The CDMO, which has been owned by different private investors over the last decade, will use the funds to broaden its ...

The firms lead an investment valuing PCI Pharma at $10 billion, see the company benefiting from broader trends.

A Philadelphia-based pharmaceutical services company has just received a massive investment from two major private equity firms, reportedly catapulting its valuation to $10 billion.

More recently, PCI acquired a 100% stake in Ajinomoto’s fill-finish contracting arm Ajinomoto Althea. The deal, for which ...

Bain Capital and Kohlberg have completed a strategic investment in PCI Pharma Services, according to a news release.

(Reuters) -Bain Capital is in talks to buy contract drug manufacturer PCI Pharma Services at a valuation of $10 billion, Bloomberg News reported on Friday, citing people familiar with the matter. The ...

PCI Pharma Services has secured a new round of strategic investment, with Bain Capital joining existing lead investor Kohlberg and reinvestment partner Mubadala Investment Company to support ...